https://aveo-staging.lumanitydigital.net/alert-window/ 2020-05-29T12:46:56+00:00 https://aveo-staging.lumanitydigital.net/kenneth-m-bate/ 2022-10-28T17:52:14+00:00 https://aveo-staging.lumanitydigital.net/kevin-cullen-m-d/ 2022-10-28T17:53:12+00:00 https://aveo-staging.lumanitydigital.net/corinne-epperly-m-d-m-p-h/ 2022-10-28T17:53:46+00:00 https://aveo-staging.lumanitydigital.net/anthony-b-evnin-ph-d/ 2022-10-28T17:54:09+00:00 https://aveo-staging.lumanitydigital.net/gregory-t-mayes/ 2022-10-28T17:55:07+00:00 https://aveo-staging.lumanitydigital.net/scarlett-spring/ 2022-10-28T17:55:40+00:00 https://aveo-staging.lumanitydigital.net/michael-p-bailey-2/ 2023-02-07T00:36:56+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-stockholders-approve-acquisition-by-lg-chem/ 2023-06-27T18:14:23+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reminds-stockholders-to-vote-for-all-cash-transaction-with-lg-chem-in-advance-of-the-special-meeting-of-stockholders/ 2023-06-27T18:31:11+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-third-quarter-2022-financial-results/ 2023-06-27T18:38:42+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/lg-chem-to-acquire-aveo-oncology-for-15-00-per-share-in-cash/ 2023-06-27T18:43:04+00:00 https://aveo-staging.lumanitydigital.net/u-s-patent-trademark-office-allows-aveo-oncologys-patent-application-covering-use-of-fotivda-for-the-treatment-of-refractory-advanced-renal-cell-carcinoma/ 2023-06-27T18:50:04+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-the-cantor-fitzgerald-oncology-hemonc-conference/ 2023-06-27T18:52:32+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-investor-conferences-in-september/ 2023-06-27T18:55:04+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-to-announce-second-quarter-2022-financial-results-on-august-4-2022/ 2023-06-27T19:02:52+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-clinical-trial-collaboration-and-supply-agreement-with-eli-lilly-and-company-for-erbitux-cetuximab-in-north-america-to-evaluate-ficlatuzumab-and-cetuximab-in-patients-w/ 2023-06-27T19:11:25+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-second-quarter-2022-financial-results/ 2023-06-27T19:16:21+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-updated-nccn-clinical-practice-guidelines-elevate-fotivda-tivozanib-to-category-1-treatment-for-relapsed-or-refractory-advanced-r-r-renal-cell-carcinoma-rcc-patient/ 2023-06-27T19:19:58+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-presents-three-posters-for-tivozanib-at-the-2022-asco-annual-meeting/ 2023-06-27T19:23:05+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-the-h-c-wainwright-global-investment-conference/ 2023-06-27T19:25:16+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-first-quarter-2022-financial-results/ 2023-06-27T19:27:48+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-to-announce-first-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-may-5-2022/ 2023-06-27T19:30:41+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-full-year-and-fourth-quarter-2021-financial-results/ 2023-06-27T19:32:52+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-to-announce-full-year-2021-financial-results-and-host-conference-call-and-webcast-on-march-14-2022/ 2023-06-27T19:35:01+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/actinium-pharmaceuticals-inc-and-aveo-oncology-enter-research-collaboration-agreement-to-develop-first-in-class-actinium-225-erbb3-targeting-radiotherapy-for-solid-tumors/ 2023-06-27T19:37:20+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-positive-new-long-term-pfs-data-from-phase-3-tivo-3-study-of-fotivda-tivozanib-in-third-and-fourth-line-renal-cell-carcinoma/ 2023-06-27T19:39:33+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-the-11th-annual-svb-leerink-global-healthcare-conference/ 2023-06-27T19:41:43+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-presents-three-posters-for-tivozanib-immunotherapy-combinations-at-the-2022-asco-gi-cancers-symposium/ 2023-06-27T19:43:51+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/nikang-therapeutics-and-aveo-oncology-announce-a-clinical-trial-collaboration-and-supply-agreement-to-evaluate-the-combination-of-nkt2152-a-hif2%ce%b1-inhibitor-and-fotivda-tivozanib-for-the/ 2023-06-27T19:46:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-highlights-recent-progress-and-2022-outlook/ 2023-06-27T19:48:32+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-clinical-trial-collaboration-and-supply-agreement-with-merck-kgaa-darmstadt-germany-to-evaluate-ficlatuzumab-and-erbitux-cetuximab-in-patients-with-recurrent-or-metas/ 2023-06-27T19:50:57+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-the-h-c-wainwright-virtual-bioconnect-2022-conference/ 2023-06-27T19:54:44+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-appointment-of-jeb-ledell-as-chief-operating-officer/ 2023-06-27T19:56:53+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-two-upcoming-virtual-investor-conferences/ 2023-06-27T19:59:12+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-third-quarter-2021-financial-results-and-provides-business-update/ 2023-06-27T20:01:11+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-announce-third-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-november-8-2021/ 2023-06-27T20:08:37+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-completion-of-enrollment-in-pivotal-phase-3-tinivo-2-study-of-fotivda-tivozanib-in-combination-with-opdivo-nivolumab-in-advanced-renal-cell-carcinoma/ 2023-06-27T21:04:52+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-ficlatuzumab-granted-fast-track-designation-by-the-u-s-fda-for-the-treatment-of-relapsed-or-recurrent-head-and-neck-squamous-cell-carcinoma/ 2023-06-28T10:05:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-two-upcoming-virtual-investor-conferences-2/ 2023-06-28T10:24:26+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-second-quarter-2021-financial-results-and-provides-business-update/ 2023-06-28T10:27:20+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-announce-second-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-august-5-2021/ 2023-06-28T10:30:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-host-key-opinion-leader-webinar-on-fotivda-tivozanib-for-relapsed-or-refractory-renal-cell-carcinoma/ 2023-06-28T10:32:33+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-host-key-opinion-leader-webinar-on-ficlatuzumab-in-head-and-neck-squamous-cell-carcinoma/ 2023-06-28T10:35:10+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-jefferies-2021-virtual-healthcare-conference/ 2023-06-28T10:37:15+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-presentation-of-long-term-efficacy-follow-up-additional-tolerability-data-from-the-phase-3-tivo-3-study-of-fotivda-tivozanib-in-relapsed-or-refractory-renal-cell-carci/ 2023-06-28T10:39:19+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-positive-results-from-randomized-phase-2-study-of-ficlatuzumab-in-combination-with-cetuximab-in-pan-refractory-metastatic-hnscc/ 2023-06-28T10:41:25+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-first-quarter-2021-financial-results-and-provides-business-update/ 2023-06-28T10:44:30+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-announce-first-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-may-10-2021/ 2023-06-28T10:46:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-appointment-of-kevin-cullen-m-d-to-its-board-of-directors/ 2023-06-28T10:48:23+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-addition-of-fotivda-tivozanib-into-national-comprehensive-cancer-network-clinical-practice-guidelines/ 2023-06-28T10:51:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-option-to-purchase-additional-shares/ 2023-06-28T10:53:55+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-pricing-of-48-0-million-public-offering-of-common-stock/ 2023-06-28T10:56:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-proposed-public-offering-of-common-stock/ 2023-06-28T10:59:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-u-s-commercial-availability-of-fotivda-tivozanib-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-advanced-renal-cell-carcinoma-ahead-of-previous-guidan/ 2023-06-28T11:03:33+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-full-year-2020-financial-results-and-provides-business-update/ 2023-06-28T11:06:57+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-regain-ex-north-american-rights-to-av-203/ 2023-06-28T11:18:26+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-collaboration-with-bristol-myers-squibb-to-evaluate-fotivda-tivozanib-in-combination-with-opdivo-nivolumab-in-pivotal-phase-3-tinivo-2-trial-in-io-relapsed-rena/ 2023-06-28T11:20:52+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-drawdown-of-20-million-tranche-under-hercules-debt-facility/ 2023-06-28T11:23:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-appointment-of-mike-ferraresso-to-chief-commercial-officer/ 2023-06-28T11:26:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-u-s-fda-approval-of-fotivda-tivozanib-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-advanced-renal-cell-carcinoma/ 2023-06-28T11:28:52+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-h-c-wainwright-global-life-sciences-conference/ 2023-06-28T11:31:39+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-the-2021-svb-leerink-global-healthcare-conference/ 2023-06-28T11:33:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-presentation-of-key-subgroup-and-quality-of-life-analyses-from-the-phase-3-tivo-3-study-of-tivozanib-in-renal-cell-carcinoma/ 2023-06-28T11:36:10+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-commitment-for-an-incremental-10-million-loan-in-addition-to-current-tranched-35-million-debt-facility-with-hercules-capital/ 2023-06-28T11:40:06+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-highlights-recent-progress-and-2021-outlook/ 2023-06-28T12:06:04+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-two-upcoming-investor-conferences/ 2023-06-28T12:07:58+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-webcast-of-presentation-at-the-39th-annual-j-p-morgan-healthcare-conference/ 2023-06-28T12:09:46+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-results-from-phase-1b-portion-of-deductive-study-of-tivozanib-fotivda-in-combination-with-imfinzi-durvalumab-in-previously-untreated-metastatic-hepatocellular-c/ 2023-06-28T12:11:17+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-stifel-2020-virtual-healthcare-conference/ 2023-06-28T13:18:15+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-third-quarter-2020-financial-results-and-provides-business-update/ 2023-06-28T13:20:33+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-eusa-pharma-announce-annals-of-oncology-publication-of-data-from-phase-1b-2-tinivo-study-in-renal-cell-carcinoma/ 2023-06-28T13:22:34+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-appointment-of-david-w-crist-as-vice-president-of-sales/ 2023-06-28T13:49:23+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-european-urology-publication-of-final-overall-survival-data-from-phase-3-tivo-3-study-of-tivozanib-in-renal-cell-carcinoma/ 2023-06-28T14:02:58+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-regains-full-global-rights-to-ficlatuzumab/ 2023-06-28T14:05:31+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-participation-at-two-upcoming-investor-conferences-2/ 2023-06-28T14:07:15+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-restructuring-of-existing-term-loan-with-closing-of-new-tranched-35-million-debt-facility/ 2023-06-28T14:09:06+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-second-quarter-2020-financial-results-and-provides-business-update/ 2023-06-28T14:10:58+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-2-8m-development-milestone-earned-from-kyowa-kirin/ 2023-06-28T14:14:17+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-closing-of-public-offering-of-common-stock-and-partial-exercise-of-option-to-purchase-additional-shares/ 2023-06-28T14:16:18+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-pricing-of-44-6-million-public-offering-of-common-stock/ 2023-06-28T14:18:21+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-proposed-public-offering-of-common-stock-2/ 2023-06-28T14:32:18+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-fda-acceptance-for-filing-of-a-new-drug-application-for-tivozanib-as-a-treatment-of-relapsed-or-refractory-renal-cell-carcinoma/ 2023-06-28T14:34:14+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-phase-1b-2-deductive-study-of-fotivda-tivozanib-in-combination-with-imfinzi-durvalumab-in-previously-untreated-metastatic-hepatocellular-carcinoma-advances-to-p/ 2023-06-28T14:42:22+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-tivo-3-final-overall-survival-results-featured-at-asco-2020-virtual-scientific-program-and-submitted-to-u-s-fda-as-part-of-nda-filing/ 2023-06-28T14:45:14+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-change-to-virtual-annual-meeting-of-stockholders/ 2023-06-28T14:58:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-first-quarter-2020-financial-results-and-provides-business-update/ 2023-06-28T15:34:57+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-final-overall-survival-analysis-from-the-phase-3-tivo-3-trial-of-tivozanib-in-renal-cell-carcinoma-at-the-asco-2020-virtual-scientific-program/ 2023-06-28T15:36:43+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-submission-of-new-drug-application-to-u-s-fda-for-tivozanib-in-patients-with-relapsed-or-refractory-renal-cell-carcinoma/ 2023-06-28T15:41:35+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-biodesix-to-discontinue-cyfi-2-study-of-ficlatuzumab-in-relapsed-and-refractory-aml-in-response-to-public-health-crisis/ 2023-06-28T15:43:27+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-full-year-2019-financial-results-and-provides-business-update/ 2023-06-28T15:45:14+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-effectiveness-of-1-for-10-reverse-stock-split/ 2023-06-28T15:47:34+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-publication-of-phase-1b-2-study-of-tivozanib-in-advanced-inoperable-liver-cancer-in-the-british-journal-of-cancer/ 2023-06-28T15:49:32+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-biodesix-announce-results-from-phase-1b-study-of-ficlatuzumab-gemcitabine-and-nab-paclitaxel-in-advanced-pancreatic-cancer/ 2023-06-28T15:51:38+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-appointment-of-erick-j-lucera-as-chief-financial-officer/ 2023-06-28T15:53:18+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-lancet-oncology-publication-of-data-from-phase-3-tivo-3-study-of-tivozanib-in-renal-cell-carcinoma/ 2023-06-28T16:45:14+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference/ 2023-06-28T17:05:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-appointment-of-scarlett-spring-to-its-board-of-directors/ 2023-06-28T17:07:25+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-presentation-of-updated-os-and-subgroup-data-from-phase-3-tivo-3-trial-of-tivozanib-in-renal-cell-carcinoma/ 2023-06-28T17:15:14+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-third-quarter-2019-financial-results-and-provides-business-update/ 2023-06-28T17:19:30+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-biodesix-announce-initiation-of-the-cyfi-2-study-a-phase-2-randomized-study-of-ficlatuzumab-in-combination-with-high-dose-cytarabine-vs-high-dose-cytarabine-alone-in-patients-with/ 2023-06-28T17:22:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-regulatory-update-for-tivozanib-in-renal-cell-carcinoma/ 2023-06-28T17:23:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-initiation-of-enrollment-in-phase-1b-2-study-of-fotivda-tivozanib-in-combination-with-imfinzi-durvalumab-in-previously-untreated-metastatic-hepatocellular-carci/ 2023-06-28T17:25:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-2019-cantor-fitzgerald-global-healthcare-conference/ 2023-06-28T17:27:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-eusa-pharma-announce-presentation-of-final-pfs-results-from-phase-2-portion-of-the-tinivo-study-in-renal-cell-carcinoma/ 2023-06-28T17:30:57+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-updated-overall-survival-hazard-ratio-of-0-99-in-phase-3-tivo-3-trial-of-tivozanib-in-renal-cell-carcinoma/ 2023-06-28T17:32:46+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-second-quarter-2019-financial-results-and-provides-business-update/ 2023-06-28T17:34:52+00:00 https://aveo-staging.lumanitydigital.net/kyowa-kirin-buys-back-tivozanib-non-oncology-rights-from-aveo-oncology/ 2023-06-28T17:36:53+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-2019-bio-international-convention/ 2023-06-28T17:38:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-presentations-at-the-2019-asco-annual-meeting/ 2023-06-28T17:40:32+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-first-quarter-2019-financial-results-and-provides-business-update/ 2023-06-28T17:42:22+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-participate-in-the-5th-annual-suntrust-robinson-humphrey-life-sciences-summit/ 2023-06-28T17:44:14+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-2m-milestone-payment-from-eusa-pharma-related-to-commercialization-of-fotivda-in-spain/ 2023-06-28T17:46:36+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-pricing-of-25-million-underwritten-public-offering/ 2023-06-28T17:48:28+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-proposed-public-offering/ 2023-06-28T17:50:31+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-h-c-wainwright-global-life-sciences-conference-2/ 2023-06-28T17:52:15+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-biodesix-announce-positive-results-from-phase-ib-ficlatuzumab-cytarabine-trial-in-patients-with-relapsed-and-refractory-aml/ 2023-06-28T17:54:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-full-year-2018-financial-results-and-provides-business-update/ 2023-06-28T17:56:39+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-appointment-of-gregory-t-mayes-to-its-board-of-directors/ 2023-06-28T17:58:25+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference/ 2023-06-28T18:01:09+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-oral-presentation-of-tivo-3-trial-topline-results-at-the-2019-asco-genitourinary-cancers-symposium/ 2023-06-28T18:02:59+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-nda-timing-update/ 2023-06-28T18:04:50+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference/ 2023-06-28T18:06:59+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-tivo-3-data-at-the-2019-asco-genitourinary-cancers-symposium/ 2023-06-28T18:10:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-immuno-oncology-clinical-collaboration-with-astrazeneca/ 2023-06-28T18:15:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-extension-of-debt-facility-interest-only-period/ 2023-06-29T06:05:20+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-30th-annual-piper-jaffray-healthcare-conference/ 2023-06-29T06:11:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-2m-milestone-payment-from-eusa-pharma-related-to-german-commercialization-of-fotivda/ 2023-06-29T06:14:11+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-third-quarter-2018-financial-results-and-provides-business-update/ 2023-06-29T06:16:08+00:00 https://aveo-staging.lumanitydigital.net/http-www-aveooncology-com-wp-content-uploads-2023-06-aveo-reports-third-quarter-2018-financial-results-and-provides-business-update-pdf/ 2023-06-29T06:18:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-eusa-pharma-announce-updated-interim-results-from-phase-2-portion-of-the-tinivo-study-in-renal-cell-carcinoma/ 2023-06-29T06:20:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-updated-interim-results-from-the-phase-2-portion-of-the-tinivo-study-of-tivozanib-and-nivolumab-opdivo-in-rcc-at-the-esmo-2018-annual-congress/ 2023-06-29T06:22:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-initiation-of-topline-analysis-of-phase-3-tivo-3-trial/ 2023-06-29T06:23:59+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-participate-in-upcoming-conferences/ 2023-06-29T06:25:57+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-participate-in-upcoming-conferences-2/ 2023-06-29T06:27:55+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-pricing-of-5-7-million-public-offering-of-common-stock/ 2023-06-29T06:29:42+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-proposed-offering-of-common-stock/ 2023-06-29T07:55:00+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-acceptance-of-canbridge-investigational-new-drug-application-for-can017-av-203-trial-in-esophageal-squamous-cell-cancer-escc-in-china/ 2023-06-29T07:56:39+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-second-quarter-2018-financial-results-and-provides-business-update/ 2023-06-29T07:58:33+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-canaccord-genuity-38th-annual-growth-conference/ 2023-06-29T08:00:04+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-issues-statement-regarding-revised-tivo-3-trial-guidance/ 2023-06-29T08:01:45+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-added-to-the-russell-2000-russell-3000-and-russell-microcap-indexes/ 2023-06-29T08:03:28+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-jefferies-2018-healthcare-conference/ 2023-06-29T08:05:12+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-first-quarter-2018-financial-results-and-provides-business-update/ 2023-06-29T08:06:46+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-upcoming-conferences/ 2023-06-29T08:08:26+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-publication-of-long-term-follow-up-results-from-tivo-1-extension-study-study-902-in-tki-refractory-rcc/ 2023-06-29T08:10:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-full-year-2017-financial-results-and-provides-business-update/ 2023-06-29T08:11:54+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-cowen-and-company-38th-annual-health-care-conference/ 2023-06-29T08:13:23+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-eusa-pharma-granted-positive-nice-recommendation-for-fotivda-tivozanib-as-first-line-treatment-for-advanced-renal-cell-carcinoma/ 2023-06-29T08:15:18+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-eusa-pharma-announce-encouraging-preliminary-results-from-phase-2-portion-of-the-tinivo-study-in-renal-cell-carcinoma/ 2023-06-29T08:16:55+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-upcoming-conferences-2/ 2023-06-29T08:18:38+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-appointment-of-john-h-johnson-to-board-of-directors/ 2023-06-29T08:20:11+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-presentation-of-data-from-phase-1b-2-study-of-tivozanib-in-patients-with-advanced-hepatocellular-carcinoma/ 2023-06-29T08:23:26+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference/ 2023-06-29T08:25:17+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-refinanced-debt-facility/ 2023-06-29T08:27:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-clinical-updates-to-tivozanib-and-ficlatuzumab-programs/ 2023-06-29T09:04:59+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-appointment-of-nikhil-mehta-ph-d-as-senior-vice-president-of-regulatory-and-quality-assurance/ 2023-06-29T09:07:20+00:00 https://aveo-staging.lumanitydigital.net/eusa-pharma-and-aveo-oncology-announce-the-first-commercial-launch-of-fotivda-tivozanib/ 2023-06-29T09:14:33+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-upcoming-conferences-3/ 2023-06-29T09:16:11+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-third-quarter-2017-financial-results-and-provides-business-update/ 2023-06-29T09:17:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-eusa-pharma-announce-promising-phase-1-results-from-the-phase-1-2-tinivo-study-of-tivozanib-and-nivolumab-in-renal-cell-carcinoma/ 2023-06-29T09:19:19+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-phase-1-results-from-tinivo-study-to-be-presented-at-the-16th-international-kidney-cancer-symposium/ 2023-06-29T09:20:55+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-completion-of-tivo-3-study-futility-analysis-with-no-changes-to-study-protocol/ 2023-06-29T09:22:33+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-eusa-pharma-announce-tinivo-combination-study-opt-in/ 2023-06-29T09:26:39+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-receipt-of-payments-from-eusa-pharma-and-canbridge/ 2023-06-29T09:28:18+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-upcoming-conferences-4/ 2023-06-29T09:30:18+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-fotivda-tivozanib-approved-in-the-european-union-for-the-treatment-of-advanced-renal-cell-carcinoma/ 2023-06-29T09:32:31+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-second-quarter-2017-financial-results-and-provides-business-update/ 2023-06-29T09:34:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-14m-in-aggregate-gross-proceeds-from-hercules-credit-facility-and-at-the-market-stock-offerings/ 2023-06-29T09:35:50+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-positive-chmp-opinion-for-tivozanib-as-a-treatment-of-advanced-renal-cell-carcinoma/ 2023-06-29T09:37:23+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-pivotal-phase-3-tivo-3-study-of-tivozanib-in-renal-cell-carcinoma-reaches-enrollment-target/ 2023-06-29T09:38:49+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-phase-1-2-tinivo-trial-of-tivozanib-and-opdivo-nivolumab-in-rcc-advances-to-phase-2/ 2023-06-29T09:40:26+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-and-biodesix-announce-results-from-two-investigator-sponsored-phase-1-studies-of-hgf-targeted-antibody-ficlatuzumab-at-the-2017-asco-annual-meeting/ 2023-06-29T09:42:07+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-completion-of-a-chmp-oral-explanation-for-tivozanib-as-a-treatment-of-first-line-renal-cell-carcinoma/ 2023-06-29T09:43:55+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-appointment-of-matthew-dallas-as-chief-financial-officer/ 2023-06-29T09:45:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-issues-statement-regarding-the-passing-of-lead-director-henri-a-termeer/ 2023-06-29T09:47:24+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-receipt-of-uspto-notice-of-allowance-related-to-av-353/ 2023-06-29T09:49:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-first-quarter-2017-financial-results-and-provides-business-update/ 2023-06-29T09:50:37+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-presentations-at-the-2017-asco-annual-meeting/ 2023-06-29T09:52:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-submission-of-response-to-tivozanib-marketing-authorization-application-day-180-list-of-outstanding-issues/ 2023-06-29T09:53:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-milestone-payment-from-canbridge-for-av-203/ 2023-06-29T09:55:53+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares/ 2023-06-29T10:23:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-pricing-of-15-0-million-public-offering-of-common-stock/ 2023-06-29T10:24:41+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-proposed-offering-of-common-stock-2/ 2023-06-29T10:26:06+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-full-year-2016-financial-results-and-provides-business-update/ 2023-06-29T10:27:52+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-first-patient-dosed-in-phase-1-2-tinivo-trial-of-tivozanib-and-opdivo-nivolumab-in-advanced-rcc/ 2023-06-29T10:29:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-tivo-3-passes-the-first-safety-monitoring-committee-safety-review/ 2023-06-29T10:31:03+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-clinical-and-regulatory-updates-for-tivozanib/ 2023-06-29T10:32:34+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-at-the-19th-annual-bio-ceo-investor-conference/ 2023-06-29T10:34:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-submission-of-responses-to-the-ema-day-120-list-of-questions-for-marketing-authorization-application-for-tivozanib-in-renal-cell-carcinoma/ 2023-06-29T13:32:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference/ 2023-06-29T13:33:39+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-third-quarter-2016-financial-results-and-provides-business-update/ 2023-06-29T13:35:27+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-at-the-15th-annual-bio-investor-forum/ 2023-06-29T13:37:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-proposed-settlement-and-settlement-hearing-in-2014-stockholder-litigation/ 2023-06-29T13:41:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-at-the-18th-annual-rodman-renshaw-global-investment-conference/ 2023-06-29T13:43:10+00:00 https://aveo-staging.lumanitydigital.net/aveo-initiates-the-evaluation-of-tivozanib-in-combination-with-bristol-myers-squibbs-opdivo-nivolumab-in-advanced-renal-cell-carcinoma/ 2023-06-29T13:44:46+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-second-quarter-2016-financial-results-and-provides-business-update/ 2023-06-29T13:46:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-at-the-2016-jmp-securities-life-science-conference/ 2023-06-29T13:48:07+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-dosing-of-first-patient-in-the-pivotal-phase-3-tivo-3-study-of-tivozanib-in-renal-cell-carcinoma/ 2023-06-29T13:49:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-closing-of-private-placement-and-amended-term-loan-to-fund-pivotal-tivo-3-trial-and-combination-pd-1-trial-of-tivozanib-in-renal-cell-cancer/ 2023-06-29T13:51:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-17-million-private-placement/ 2023-06-29T13:53:00+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-first-quarter-2016-financial-results-and-provides-business-update/ 2023-06-29T13:54:35+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-filing-of-provisional-patent-applications-for-av-353-a-notch-3-specific-inhibitor-antibody-for-pah/ 2023-06-29T13:56:12+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-canbridge-life-sciences-announce-exclusive-licensing-agreement-for-av-203-outside-of-north-america/ 2023-06-29T13:57:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-full-year-2015-financial-results-and-provides-business-update/ 2023-06-29T14:00:08+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-at-the-28th-annual-roth-conference/ 2023-06-29T14:01:38+00:00 https://aveo-staging.lumanitydigital.net/eusa-pharma-and-aveo-announce-submission-of-marketing-authorization-application-for-tivozanib-in-advanced-renal-cell-carcinoma/ 2023-06-29T14:03:13+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-acceptance-of-registration-dossier-for-tivozanib-in-rcc-by-the-ministry-of-health-of-the-russian-federation/ 2023-06-29T14:04:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-at-the-18th-annual-bio-ceo-investor-conference/ 2023-06-29T14:06:21+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-at-biotech-showcase-2016/ 2023-06-29T14:08:08+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-eusa-pharma-announce-exclusive-licensing-agreement-for-tivozanib-in-europe/ 2023-06-29T17:10:40+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-third-quarter-2015-financial-results-and-provides-business-update/ 2023-06-29T17:12:41+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-chairman-tuan-ha-ngoc-steps-down/ 2023-06-29T17:14:27+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-exclusive-worldwide-license-agreement-for-the-development-and-commercialization-of-av-380-and-related-antibodies/ 2023-06-29T17:16:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-second-quarter-2015-financial-results/ 2023-06-29T17:17:40+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-host-midyear-update-conference-call-on-august-10-2015/ 2023-06-29T17:20:59+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-exclusive-licensing-agreement-with-pharmstandard-for-tivozanib-in-russia-ukraine-and-cis/ 2023-06-29T17:22:37+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-additional-biomarker-analyses-from-baton-crc-tivozanib-study-to-be-presented-at-the-esmo-17th-world-congress-on-gastrointestinal-cancer/ 2023-06-29T17:24:55+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-fda-update-for-tivozanib-in-colorectal-cancer/ 2023-06-29T17:26:30+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-receipt-of-european-regulatory-guidance-regarding-potential-marketing-authorization-application-for-tivozanib/ 2023-06-29T17:28:22+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-jefferies-2015-global-healthcare-conference/ 2023-06-29T17:30:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-new-corporate-headquarters-in-cambridge-massachusetts/ 2023-06-29T17:31:39+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-presentation-of-final-results-of-extension-study-902-and-fda-regulatory-feedback-for-advancing-tivozanib-in-renal-cell-carcinoma/ 2023-06-29T17:33:19+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-first-quarter-2015-financial-results/ 2023-06-29T17:35:42+00:00 https://aveo-staging.lumanitydigital.net/aveo-names-keith-s-ehrlich-as-chief-financial-officer/ 2023-06-29T17:37:24+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-presentation-of-av-380-preclinical-data-in-cancer-associated-cachexia-at-2015-annual-meeting-of-the-american-association-of-cancer-research/ 2023-06-29T17:39:17+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-full-year-2014-financial-results/ 2023-06-29T17:40:51+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-presentation-of-phase-2-study-analysis-showing-longer-pfs-with-tivozanib-compared-to-bevacizumab-in-low-serum-nrp-1-patients-with-advanced-crc/ 2023-06-29T17:42:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-host-conference-call-to-discuss-presentation-of-final-results-and-biomarker-analysis-from-phase-2-study-of-tivozanib-in-patients-with-advanced-colorectal-cancer/ 2023-06-29T17:44:04+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference/ 2023-06-29T17:45:41+00:00 https://aveo-staging.lumanitydigital.net/aveo-names-michael-n-needle-m-d-as-chief-medical-officer/ 2023-06-29T17:47:19+00:00 https://aveo-staging.lumanitydigital.net/aveo-receives-confirmation-of-eligibility-for-submission-of-a-tivozanib-marketing-authorization-application-to-the-european-medicines-agency/ 2023-06-29T17:49:10+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-executive-transition-and-corporate-restructuring/ 2023-06-29T17:50:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-enters-into-research-and-exclusive-option-agreement-with-ophthotech-for-tivozanib-vegf-inhibitor-for-the-treatment-of-ocular-diseases/ 2023-06-30T05:50:56+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-third-quarter-2014-financial-results/ 2023-06-30T05:52:34+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-results-from-phase-2-clinical-studies-of-tivozanib-in-patients-with-advanced-colorectal-and-kidney-cancers-presented-at-esmo-2014-congress/ 2023-06-30T05:54:22+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-biodesix-announce-exploratory-analysis-of-veristrat-selected-patients-with-non-small-cell-lung-cancer-in-phase-2-study-of-ficlatuzumab-presented-at-esmo-2014-congress/ 2023-06-30T05:55:50+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-presentation-of-av-380-preclinical-data-at-2nd-cancer-cachexia-conference/ 2023-06-30T05:59:56+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-lease-termination-and-amendment-to-debt-financing-facility/ 2023-06-30T06:02:11+00:00 https://aveo-staging.lumanitydigital.net/clinical-data-on-aveo-oncologys-ficlatuzumab-and-tivozanib-to-be-presented-at-the-esmo-2014-congress/ 2023-06-30T06:04:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-second-quarter-2014-financial-results-and-updates-progress-on-strategic-plan/ 2023-06-30T06:06:11+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-presentation-of-av-203-phase-1-results-at-2014-american-society-of-clinical-oncology-annual-meeting/ 2023-06-30T06:08:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-jefferies-global-healthcare-conference/ 2023-06-30T06:09:40+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-first-quarter-2014-financial-results/ 2023-06-30T06:11:23+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-report-first-quarter-2014-financial-results-on-may-7-2014/ 2023-06-30T06:12:58+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-biodesix-partner-to-co-develop-and-commercialize-ficlatuzumab-with-a-companion-diagnostic-for-treatment-of-nsclc/ 2023-06-30T06:14:35+00:00 https://aveo-staging.lumanitydigital.net/aveo-regains-worldwide-rights-to-av-203/ 2023-06-30T06:16:21+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-reports-full-year-2013-financial-results-and-outlines-2014-strategic-plan/ 2023-06-30T06:17:58+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-timing-for-conference-call-to-discuss-year-end-2013-financial-results-and-provide-strategic-update-for-2014/ 2023-06-30T06:19:27+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-to-end-worldwide-collaboration-license-agreement-for-development-and-commercialization-of-tivozanib/ 2023-06-30T06:21:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-discontinue-phase-2-trial-of-tivozanib-in-breast-cancer/ 2023-06-30T06:23:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-provides-update-on-interim-analysis-from-tivozanib-trial-in-colorectal-cancer/ 2023-06-30T07:52:11+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-third-quarter-2013-financial-results/ 2023-06-30T07:54:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-morgan-stanley-global-healthcare-conference/ 2023-06-30T07:56:19+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-canaccord-genuity-33rd-annual-growth-conference/ 2023-06-30T08:11:09+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-second-quarter-2013-financial-results/ 2023-06-30T08:12:52+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-complete-response-letter-received-for-tivozanib-new-drug-application-in-renal-cell-carcinoma/ 2023-06-30T08:14:24+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-strategic-restructuring/ 2023-06-30T08:15:57+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-presentations-of-tivozanib-clinical-data-at-2013-american-society-of-clinical-oncology-annual-meeting/ 2023-06-30T08:17:45+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-report-fda-oncologic-drug-advisory-committee-votes-tivozanib-application-did-not-demonstrate-favorable-benefit-to-risk-evaluation-in-treatment-of-advanced-renal-cell-carcinoma/ 2023-06-30T08:19:25+00:00 https://aveo-staging.lumanitydigital.net/trading-of-aveo-common-stock-halted/ 2023-06-30T08:23:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-first-quarter-2013-financial-results/ 2023-06-30T08:24:42+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-barclays-global-healthcare-conference/ 2023-06-30T08:26:31+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-fda-advisory-committee-to-review-tivozanib-for-the-treatment-of-advanced-renal-cell-carcinoma/ 2023-06-30T08:33:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-2013-rbc-capital-markets-healthcare-conference/ 2023-06-30T08:35:23+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-2012-financial-results-and-highlights-recent-accomplishments/ 2023-06-30T08:37:06+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-report-final-overall-survival-results-from-tivo-1/ 2023-06-30T08:38:43+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-timing-for-fourth-quarter-and-year-end-2012-financial-results-conference-call/ 2023-06-30T08:40:23+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-presentations-of-tivozanib-clinical-data-at-2013-asco-genitourinary-cancers-symposium/ 2023-06-30T08:42:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-closing-of-public-offering/ 2023-06-30T08:45:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-exercise-of-over-allotment-option-for-recent-public-offering/ 2023-06-30T08:46:35+00:00 https://aveo-staging.lumanitydigital.net/aveo-prices-public-offering-of-common-stock/ 2023-06-30T08:48:12+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-proposed-public-offering-of-common-stock-3/ 2023-06-30T08:49:43+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-31st-annual-j-p-morgan-healthcare-conference/ 2023-06-30T11:33:12+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-appoints-robert-epstein-m-d-m-s-to-its-board-of-directors/ 2023-06-30T11:34:46+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-initiation-of-patient-enrollment-in-phase-2-trial-of-tivozanib-in-combination-with-paclitaxel-in-patients-with-advanced-triple-negative-breast-cancer/ 2023-06-30T11:36:21+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-fda-acceptance-of-nda-filing-for-tivozanib-for-the-treatment-of-advanced-renal-cell-carcinoma/ 2023-06-30T11:38:21+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-deutsche-bank-2012-dbaccess-biofest-conference/ 2023-06-30T11:45:19+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-lazard-capital-markets-9th-annual-healthcare-conference/ 2023-06-30T11:47:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-strategic-restructuring-and-provides-third-quarter-financial-results/ 2023-06-30T11:48:38+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-timing-for-third-quarter-financial-results-webcast-and-conference-call/ 2023-06-30T11:50:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-new-data-presented-at-esmo-2012-congress-demonstrating-the-safety-and-tolerability-profile-of-tivozanib-in-patients-with-advanced-kidney-cancer/ 2023-06-30T11:51:30+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-detailed-results-of-exploratory-phase-2-study-evaluating-ficlatuzumab-in-first-line-patients-with-advanced-non-small-cell-lung-cancer-new-data-presented-at-esmo/ 2023-06-30T11:53:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-submission-of-new-drug-application-for-tivozanib-for-the-treatment-of-advanced-renal-cell-carcinoma/ 2023-06-30T11:54:40+00:00 https://aveo-staging.lumanitydigital.net/new-clinical-data-on-aveo-oncologys-tivozanib-and-ficlatuzumab-to-be-presented-at-the-esmo-2012-congress/ 2023-06-30T11:56:12+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-ubs-annual-global-life-sciences-conference/ 2023-06-30T11:57:49+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-morgan-stanley-global-healthcare-conference-2/ 2023-06-30T11:59:30+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-canaccord-genuity-32nd-annual-growth-conference/ 2023-06-30T12:01:03+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-second-quarter-2012-financial-results/ 2023-06-30T12:02:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-timing-for-second-quarter-financial-results-webcast-and-conference-call/ 2023-06-30T12:04:07+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-taurus-patient-preference-clinical-study-comparing-tivozanib-with-sunitinib-in-first-line-kidney-cancer/ 2023-06-30T12:05:51+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-host-conference-call-and-webcast-to-review-phase-3-tivo-1-data-presented-at-asco/ 2023-06-30T12:07:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-to-present-at-the-jefferies-2012-global-healthcare-conference/ 2023-06-30T12:08:43+00:00 https://aveo-staging.lumanitydigital.net/aveo-initiates-phase-1-study-of-av-203-an-erbb3-inhibitory-antibody-in-advanced-solid-tumors/ 2023-06-30T12:10:13+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-positive-findings-from-tivo-1-superiority-study-of-tivozanib-in-first-line-advanced-rcc/ 2023-06-30T12:11:33+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-first-quarter-2012-financial-results-and-recent-developments/ 2023-06-30T12:13:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-preliminary-results-of-exploratory-phase-2-study-evaluating-hgf-inhibitor-in-first-line-patients-with-advanced-lung-cancer/ 2023-06-30T12:14:28+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-upcoming-investment-conferences/ 2023-06-30T12:15:53+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-timing-for-first-quarterfinancial-results-webcast-and-conference-call/ 2023-06-30T12:21:10+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-publication-of-positive-tivozanib-phase-2-clinicaltrial-results-in-journal-of-clinical-oncology/ 2023-06-30T12:25:59+00:00 https://aveo-staging.lumanitydigital.net/data-on-aveo-pharmaceuticals-tivozanib-and-av-203-to-be-presented-at-aacr-annual-meeting-2012/ 2023-06-30T12:27:30+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-cowen-and-company-32nd-annual-health-care-conference/ 2023-06-30T12:29:09+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-2011-financial-results-and-highlights-fourth-quarter-progress/ 2023-06-30T12:31:32+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-timing-for-fourth-quarter-and-year-end-2011-financial-results-webcast-and-conference-call/ 2023-06-30T12:37:34+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-several-upcoming-investment-conferences/ 2023-06-30T12:46:49+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-astellas-announce-tivozanib-successfully-demonstrated-progression-free-survival-superiority-over-sorafenib-in-patients-with-advanced-renal-cell-cancer-in-phase-3-tivo-1-trial/ 2023-06-30T12:48:25+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-webcast-and-conference-call/ 2023-06-30T12:49:56+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-30th-annual-j-p-morgan-healthcare-conference/ 2023-06-30T15:53:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-patient-enrollment-in-phase-2-clinical-trial-of-tivozanib-in-combination-with-mfolfox6-in-patients-with-advanced-colorectal-cancer/ 2023-06-30T15:54:45+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-and-boehringer-ingelheim-announce-manufacturing-agreement-for-ficlatuzumab/ 2023-06-30T15:56:13+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-tivozanib-clinical-data-at-upcoming-oncology-medical-congresses/ 2023-06-30T15:57:49+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-reports-third-quarter-2011-financial-results/ 2023-06-30T15:59:52+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-timing-for-third-quarter-2011-financial-results-webcast-and-conference-call/ 2023-06-30T16:01:51+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-upcoming-investment-conferences-2/ 2023-06-30T16:03:26+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-the-canaccord-genuity-31st-annual-growth-conference/ 2023-06-30T16:05:13+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-second-quarter-2011-accomplishments-and-financial-results/ 2023-06-30T16:07:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-timing-for-second-quarter-2011-financial-results-webcast-and-conference-call/ 2023-06-30T16:08:33+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-announces-closing-and-exercise-of-over-allotment-option-for-recent-public-offering/ 2023-06-30T16:10:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-prices-public-offering-of-common-stock/ 2023-06-30T16:11:25+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-announces-proposed-public-offering-of-common-stock/ 2023-06-30T16:12:50+00:00 https://aveo-staging.lumanitydigital.net/aveos-ficlatuzumab-in-combination-with-gefitinib-well-tolerated-in-patients-with-non-small-cell-lung-cancer-phase-1b-data-presented-at-asco/ 2023-06-30T16:14:18+00:00 https://aveo-staging.lumanitydigital.net/final-analysis-from-aveo-pharmaceuticals-phase-2-trial-of-tivozanib-in-patients-with-advanced-renal-cell-carcinoma-presented-at-asco/ 2023-06-30T16:15:50+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-enters-into-worldwide-license-agreement-with-centocor-ortho-biotech-to-develop-and-commercialize-ron-targeted-antibodies/ 2023-06-30T16:17:22+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-the-jefferies-2011-global-healthcare-conference/ 2023-06-30T16:19:03+00:00 https://aveo-staging.lumanitydigital.net/clinical-data-evaluating-aveo-pharmaceuticals-tivozanib-and-ficlatuzumab-to-be-presented-at-the-american-society-of-clinical-oncology-asco-2011-annual-meeting/ 2023-06-30T16:20:32+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-first-quarter-2011-accomplishments-and-financial-results/ 2023-06-30T16:22:07+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-the-deutsche-bank-securities-36th-annual-health-care-conference/ 2023-06-30T16:23:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-timing-for-first-quarter-2011-financial-results-webcast-and-conference-call/ 2023-06-30T16:25:14+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-appoints-henri-a-termeer-to-its-board-of-directors/ 2023-06-30T16:26:43+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-the-leerink-swann-cancer-roundtable-conference/ 2023-06-30T16:28:06+00:00 https://aveo-staging.lumanitydigital.net/preclinical-data-on-aveo-pharmaceuticals-tivozanib-and-monoclonal-antibody-pipeline-to-be-presented-at-aacr-102nd-annual-meeting-2011/ 2023-06-30T16:29:35+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-several-upcoming-investment-conferences/ 2023-06-30T16:31:11+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-2010-financial-results-and-highlights-progress-with-tivozanib-and-ficlatuzumab/ 2023-06-30T16:32:52+00:00 https://aveo-staging.lumanitydigital.net/astellas-and-aveo-pharmaceuticals-enter-into-worldwide-agreement-to-develop-and-commercialize-tivozanib-outside-of-asia/ 2023-06-30T16:34:20+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-tivozanib-clinical-data-featured-at-the-2011-asco-genitourinary-cancers-symposium/ 2023-06-30T16:35:52+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-timing-for-2010-financial-results-webcast-and-conference-call/ 2023-06-30T16:37:20+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-receives-usan-name-for-novel-internally-discovered-anti-hgf-c-met-pathway-antibody/ 2023-06-30T16:38:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-initiates-enrollment-in-a-phase-2-exploratory-biomarker-study-of-tivozanib/ 2023-06-30T16:40:09+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-tivozanib-clinical-data-featured-at-2011-asco-gastrointestinal-cancers-symposium/ 2023-06-30T16:41:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-29th-annual-j-p-morgan-healthcare-conference/ 2023-06-30T16:43:24+00:00 https://aveo-staging.lumanitydigital.net/aveos-tivozanib-in-combination-with-paclitaxel-demonstrates-safety-in-patients-with-metastatic-breast-cancer-data-presented-at-san-antonio-breast-cancer-symposium/ 2023-07-03T08:01:20+00:00 https://aveo-staging.lumanitydigital.net/new-clinical-data-evaluating-aveos-tivozanib-in-combination-with-paclitaxel-to-be-presented-at-33rd-annual-san-antonio-breast-cancer-symposium/ 2023-07-03T08:02:52+00:00 https://aveo-staging.lumanitydigital.net/osi-pharmaceuticals-inc-exercises-option-under-discovery-and-translational-research-collaboration-with-aveo/ 2023-07-03T08:08:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-several-upcoming-investment-conferences-2/ 2023-07-03T08:16:03+00:00 https://aveo-staging.lumanitydigital.net/aveos-anti-ron-monoclonal-antibody-program-highlighted-in-late-breaker-plenary-presentation-at-eortc-nci-aacr-symposium/ 2023-07-03T08:18:35+00:00 https://aveo-staging.lumanitydigital.net/aveos-tivozanib-in-combination-with-folfox6-demonstrates-anti-tumor-activity-and-safety-in-advanced-gi-cancers-results-presented-at-eortc-nci-aacr-symposium/ 2023-07-03T08:20:33+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-initiates-patient-enrollment-in-phase-1b-tivozanib-combination-trial-in-advanced-solid-tumors/ 2023-07-03T08:22:07+00:00 https://aveo-staging.lumanitydigital.net/aveo-to-present-new-clinical-data-evaluating-tivozanib-in-combination-with-folfox6-at-eortc-nci-aacr-symposium/ 2023-07-03T08:23:32+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-third-quarter-2010-financial-results-and-recent-developments/ 2023-07-03T08:24:59+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-tivozanib-recognized-as-one-of-windhovers-2011-top-10-oncology-projects-to-watch/ 2023-07-03T08:26:21+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-announces-61-million-private-placement/ 2023-07-03T08:49:28+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-timing-for-third-quarter-2010-financial-results-webcast-and-conference-call/ 2023-07-03T08:51:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-tivozanib-clinical-data-featured-at-esmo/ 2023-07-03T08:52:35+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-tivozanib-featured-at-ninth-international-kidney-cancer-symposium/ 2023-07-03T08:54:04+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-regains-worldwide-rights-to-develop-and-commercialize-anti-hgf-antibody-candidate-av-299/ 2023-07-03T08:56:10+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-upcoming-oncology-medical-meetings-and-investment-conference/ 2023-07-03T08:57:34+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-appoints-michael-p-bailey-to-the-newly-created-position-of-chief-commercial-officer/ 2023-07-03T08:59:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-several-upcoming-investment-conferences-3/ 2023-07-03T09:02:00+00:00 https://aveo-staging.lumanitydigital.net/aveo-achieves-enrollment-target-ahead-of-schedule-for-pivotal-phase-3-trial-of-tivozanib-in-patients-with-advanced-renal-cell-carcinoma/ 2023-07-03T09:04:08+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-to-present-at-the-canaccord-genuity-30th-annual-global-growth-conference/ 2023-07-03T09:05:28+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-cancer-stem-cells-the-tumor-microenvironment-conference/ 2023-07-03T09:06:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-second-quarter-2010-accomplishments-and-financial-results/ 2023-07-03T09:08:24+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-timing-for-second-quarter-2010-financial-results-webcast-and-conference-call/ 2023-07-03T09:09:51+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-human-response-platformtm-and-proprietary-mouse-models-featured-in-nature-reviews-cancer/ 2023-07-03T09:11:19+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-added-to-russell-2000r-index-and-sp-midcap-400/ 2023-07-03T09:12:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-receives-orphan-medicinal-product-designation-for-tivozanib-for-the-treatment-of-renal-cell-carcinoma-by-the-european-medicines-agency/ 2023-07-03T09:14:04+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-close-nasdaq-stock-market-on-june-22-2010/ 2023-07-03T09:15:35+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-granted-patents-for-diagnostic-tests-to-identify-patient-populations-likely-to-respond-to-tivozanib-treatment/ 2023-07-03T09:17:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-tivozanib-demonstrates-progression-free-survival-of-14-8-months-in-subgroup-of-patients-with-advanced-kidney-cancer-extended-duration-of-treatment-continues-to-highlight-favora/ 2023-07-03T09:18:46+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-initiates-phase-2-clinical-trial-evaluating-sch-900105-av-299-in-non-small-cell-lung-cancer/ 2023-07-03T09:20:36+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-2010-smid-cap-conference/ 2023-07-03T09:22:12+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-american-society-of-clinical-oncology-asco-2010-annual-meeting/ 2023-07-03T09:23:41+00:00 https://aveo-staging.lumanitydigital.net/aveo-reports-first-quarter-2010-financial-results/ 2023-07-03T09:25:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-timing-for-first-quarter-2010-financial-results-webcast-and-conference-call/ 2023-07-03T09:26:26+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-selective-anti-notch1-monoclonal-antibody-exhibits-potent-notch1-inhibitory-activity/ 2023-07-03T09:28:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-receives-milestone-payment-from-biogen-idec-under-licensing-agreement-for-erbb3-antibody-program/ 2023-07-03T09:29:37+00:00 https://aveo-staging.lumanitydigital.net/data-from-aveo-pharmaceuticals-translational-research-platform-and-novel-antibody-pipeline-to-be-presented-at-aacr-101st-annual-meeting-2010/ 2023-07-03T09:31:01+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-exercise-of-over-allotment-option-for-recent-initial-public-offering/ 2023-07-03T09:32:27+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-completes-initial-public-offering/ 2023-07-03T09:33:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-inc-announces-pricing-of-its-initial-public-offering/ 2023-07-03T09:35:10+00:00 https://aveo-staging.lumanitydigital.net/aveo-initiates-enrollment-in-phase-3-clinical-trial-evaluating-tivozanib-in-advanced-renal-cell-cancer/ 2023-07-03T09:36:37+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-files-registration-statement-for-initial-public-offering/ 2023-07-04T09:49:23+00:00 https://aveo-staging.lumanitydigital.net/aveos-triple-vegf-receptor-inhibitor-tivozanib-in-combination-with-mtor-inhibitor-demonstrates-anti-tumor-activity-and-tolerability-in-advanced-kidney-cancer-preliminary-results-presented-at-aacr-n/ 2023-07-04T09:53:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-appoints-william-j-slichenmyer-m-d-sc-m-as-chief-medical-officer-and-robert-c-young-m-d-to-board-of-directors/ 2023-07-04T09:59:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-rodman-renshaw-11th-annual-healthcare-conference/ 2023-07-04T10:03:46+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-canaccord-adams-29th-annual-global-growth-conference/ 2023-07-04T10:29:43+00:00 https://aveo-staging.lumanitydigital.net/aveos-tivozanib-demonstrates-anti-tumor-activity-in-engineered-lung-tumors-exhibiting-treatment-resistant-mutations/ 2023-07-04T10:56:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-ibcs-new-frontiers-in-cancer-drug-development-conference/ 2023-07-06T09:38:44+00:00 https://aveo-staging.lumanitydigital.net/osi-pharmaceuticals-and-aveo-pharmaceuticals-expand-oncology-discovery-and-translational-research-collaboration/ 2023-07-06T09:40:42+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-granted-patent-for-protection-of-its-directed-complementation-technology/ 2023-07-06T09:42:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-granted-patent-for-predictive-biomarker-used-to-identify-human-tumors-likely-to-respond-to-notch-pathway-inhibition/ 2023-07-06T09:44:17+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-8th-annual-needham-company-life-sciences-conference/ 2023-07-06T09:45:38+00:00 https://aveo-staging.lumanitydigital.net/av-951-demonstrates-prolonged-progression-free-survival-and-excellent-safety-profile-in-patients-with-advanced-kidney-cancer-phase-2-data-presented-at-asco/ 2023-07-06T09:51:05+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-several-key-upcoming-medical-and-industry-conferences/ 2023-07-06T09:52:28+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-scientific-advisory-board-members-recognized-for-contributions-to-cancer-research-and-medicine/ 2023-07-06T09:53:57+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-positive-finding-for-triple-vegf-receptor-inhibitor-av-951/ 2023-07-06T10:00:42+00:00 https://aveo-staging.lumanitydigital.net/aveo-presents-novel-hgf-model-and-promising-preclinical-activity-to-support-lead-antibody-agent-sch-900105-av-299/ 2023-07-06T10:02:18+00:00 https://aveo-staging.lumanitydigital.net/data-on-aveo-pharmaceuticals-av-951-in-liver-cancer-model-and-preclinical-activity-in-sch-900105-av-299-to-be-presented-at-aacr-100th-annual-meeting/ 2023-07-06T10:03:52+00:00 https://aveo-staging.lumanitydigital.net/breakthrough-preclinical-model-for-human-cancer-may-dramatically-improve-development-of-effective-oncology-drugs-data-published-in-pnas/ 2023-07-06T10:05:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-future-leaders-in-the-biotech-industry-conference/ 2023-07-06T10:07:21+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-biogen-idec-form-strategic-alliance-for-development-and-commercialization-of-erbb3-targeted-antibodies/ 2023-07-06T10:08:52+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-selected-to-present-at-insideventures-debut-investor-conference/ 2023-07-06T10:10:19+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-biogen-idec-form-strategic-alliance-for-development-and-commercialization-of-erbb3-targeted-antibodies-2/ 2023-07-06T10:11:46+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-cowen-and-company-29th-annual-health-care-conference/ 2023-07-06T10:13:07+00:00 https://aveo-staging.lumanitydigital.net/aveo-initiates-phase-1b-2a-clinical-trial-of-novel-triple-vegf-receptor-inhibitor/ 2023-07-06T10:14:35+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-barclays-global-healthcare-conference/ 2023-07-06T10:16:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-oral-triple-vegf-receptor-inhibitor-av-951-shows-robust-activity-in-patients-with-advanced-kidney-cancer/ 2023-07-06T10:17:44+00:00 https://aveo-staging.lumanitydigital.net/aveo-initiates-phase-1b-2a-combination-trial-of-novel-triple-vegf-receptor-inhibitor/ 2023-07-06T10:19:21+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-massachusetts-biotechnology-council/ 2023-07-06T10:21:02+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-announces-oral-presentation-of-data-from-av-951-phase-2-clinical-trial-at-the-2009-genitourinary-symposium/ 2023-07-06T10:22:26+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-27th-annual-j-p-morgan-healthcare-conference/ 2023-07-06T10:23:53+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-lazard-capital-markets-fifth-annual-healthcare-conference/ 2023-07-06T12:43:08+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-first-annual-boston-biotech-rd-conference/ 2023-07-06T12:44:30+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-third-annual-jmp-securities-healthcare-focus-conference/ 2023-07-06T12:45:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-initiates-first-clinical-trial-of-novel-hgf-antagonist-in-patients-with-advanced-solid-tumors-and-lymphomas/ 2023-07-06T12:47:09+00:00 https://aveo-staging.lumanitydigital.net/aveo-initiates-phase-1b-combination-trial-of-av-951-with-folfox6-in-patients-with-advanced-colorectal-and-other-gastrointestinal-cancers/ 2023-07-06T12:48:30+00:00 https://aveo-staging.lumanitydigital.net/dyax-corp-and-aveo-pharmaceuticals-announce-antibody-library-license-agreement/ 2023-07-06T12:49:53+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-completes-enrollment-in-phase-2-clinical-trial-of-av-951-in-patients-with-metastatic-renal-cell-carcinoma/ 2023-07-06T12:51:23+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-granted-patent-for-unique-genetic-screen-to-identify-novel-cancer-drug-targets/ 2023-07-06T12:52:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-2008-citi-investment-research-global-health-care-conference/ 2023-07-06T12:54:06+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-participate-in-leerink-swann-solid-tumors-roundtable-conference/ 2023-07-06T12:55:26+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-novel-triple-vegf-receptor-inhibitor-shows-tumor-regression-in-patients-with-advanced-renal-cancer-clinical-activity-and-tolerability-in-other-solid-tumors-including-col/ 2023-07-06T12:56:51+00:00 https://aveo-staging.lumanitydigital.net/new-clinical-data-on-aveo-pharmaceuticals-investigational-triple-vegfr-small-molecule-inhibitor-av-951-to-be-presented-at-aacr-annual-meeting/ 2023-07-06T12:58:06+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-future-leaders-in-the-biotech-industry-conference-2/ 2023-07-06T12:59:28+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-cowen-and-company-28th-annual-health-care-conference/ 2023-07-06T13:00:51+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-the-10th-annual-bio-ceo-investor-conference/ 2023-07-06T13:02:17+00:00 https://aveo-staging.lumanitydigital.net/aveo-initiates-phase-1b-combination-clinical-trial-of-novel-triple-vegf-receptor-inhibitor-av-951-in-metastatic-renal-cell-carcinoma/ 2023-07-06T13:03:55+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-merrill-lynch-global-pharmaceutical-biotechnology-and-medical-device-conference/ 2023-07-06T13:05:19+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-appoints-kenneth-m-bate-to-board-of-directors/ 2023-07-06T13:06:41+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-26th-annual-jpmorgan-healthcare-conference/ 2023-07-06T13:07:57+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-and-lilly-sign-collaboration-for-clinical-drug-response-project/ 2023-07-06T14:02:38+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-lazard-capital-markets-4th-annual-healthcare-conference/ 2023-07-06T14:03:58+00:00 https://aveo-staging.lumanitydigital.net/preclinical-data-published-in-cancer-science-show-aveos-novel-oral-egfr-inhibitor-av-412-effective-in-drug-resistant-cancers/ 2023-07-06T14:05:22+00:00 https://aveo-staging.lumanitydigital.net/results-from-phase-1-study-of-aveos-novel-triple-vegf-receptor-inhibitor-av-951-show-100-of-renal-cell-cancer-patients-achieved-partial-response-or-stable-disease/ 2023-07-06T14:06:42+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-present-at-acumen-biofin-rodman-renshaw-9th-annual-healthcare-conference/ 2023-07-06T14:07:59+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-appoints-david-johnston-as-cfo/ 2023-07-06T14:09:18+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-to-utilize-peptechs-breakthrough-technology-to-humanise-internal-drug-candidates/ 2023-07-06T14:10:36+00:00 https://aveo-staging.lumanitydigital.net/aveo-announces-successful-completion-of-discovery-agreement-for-novel-cancer-drugs/ 2023-07-06T14:11:57+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-ceo-tuan-ha-ngoc-receives-ernst-young-new-england-entrepreneur-of-the-year-award/ 2023-07-06T14:13:15+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-closes-53-million-in-series-d-funding/ 2023-07-06T14:14:28+00:00 https://aveo-staging.lumanitydigital.net/novel-human-tissue-transgenic-cancer-model-may-offer-significant-advance-toward-accurately-modeling-human-cancer/ 2023-07-06T14:15:47+00:00 https://aveo-staging.lumanitydigital.net/aveo-presents-preclinical-efficacy-data-on-av-412-a-novel-oral-tyrosine-kinase-inhibitor-of-egfr-her2-for-egfr-mutant-and-drug-resistant-lung-cancer/ 2023-07-06T14:17:12+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-novel-oncology-research-platform-and-clinical-pipeline-to-be-featured-at-aacr/ 2023-07-06T14:18:31+00:00 https://aveo-staging.lumanitydigital.net/aveo-enters-into-worldwide-license-and-development-agreement-with-schering-plough-for-av-299-aveos-novel-anti-hgf-antibody/ 2023-07-06T14:19:53+00:00 https://aveo-staging.lumanitydigital.net/aveo-acquires-clinical-stage-anti-cancer-compound-from-kirin/ 2023-07-06T14:21:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-initiates-clinical-development-of-av-412-in-cancer-patients-with-advanced-solid-tumors/ 2023-07-06T14:22:40+00:00 https://aveo-staging.lumanitydigital.net/aveo-and-xoma-enter-into-supply-agreement-for-aveos-novel-anti-hgf-antibody/ 2023-07-06T14:24:07+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-selected-to-receive-pharmaceutical-industry-standard-of-excellence-webaward-by-web-marketing-association/ 2023-07-06T14:25:34+00:00 https://aveo-staging.lumanitydigital.net/xoma-and-aveo-announce-agreement-to-apply-human-engineering-technology-to-av-299-aveos-novel-anti-hgf-antibody/ 2023-07-06T14:26:54+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-presents-a-novel-system-for-the-generation-of-fully-human-breast-tumors-in-mice-at-aacr-2006/ 2023-07-06T14:28:52+00:00 https://aveo-staging.lumanitydigital.net/av-412-preclinical-efficacy-data-presented-at-aacr-2006/ 2023-07-06T14:30:24+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-appoints-john-ryan-ph-d-m-d-as-chief-medical-officer/ 2023-07-06T14:32:01+00:00 https://aveo-staging.lumanitydigital.net/hercules-provides-15-0m-financing-to-aveo-pharmaceuticals-inc-a-biopharmaceutical-company-focused-on-the-discovery-and-development-of-novel-cancer-medicines/ 2023-07-06T14:33:25+00:00 https://aveo-staging.lumanitydigital.net/aveo-pharmaceuticals-acquires-rights-to-novel-anti-cancer-compound-from-mitsubishi-pharma-corporation/ 2023-07-06T14:34:43+00:00 https://aveo-staging.lumanitydigital.net/lg-chem-completes-acquisition-of-aveo-oncology/ 2023-07-06T20:03:39+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-earns-spot-on-boston-globes-2023-top-places-to-work-list-for-second-consecutive-year/ 2023-11-30T16:49:57+00:00 https://aveo-staging.lumanitydigital.net/wp-content/uploads/2023/01/AVEO_LG-Chem_Logo.png https://aveo-staging.lumanitydigital.net/aveo-oncology-enrolls-first-patient-in-pivotal-fierce-hnclinical-trial-to-evaluate-ficlatuzumab-in-combination-witherbitux-cetuximab/ 2024-01-17T15:04:57+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-publication-of-long-term-survivalin-patients-with-relapsed-refractory-advanced-renal-cellcarcinoma-treated-with-tivozanib-analysis-of-the-phase-iiitivo-3-trial-in-the-oncologi/ 2024-02-06T15:48:52+00:00 https://aveo-staging.lumanitydigital.net/correction-aveo-oncology-announces-appointment-of-chief-medical-officer-and-formation-of-scientific-advisory-committee/ 2024-03-28T20:52:17+00:00 https://aveo-staging.lumanitydigital.net/gp369-an-fgfr2-iiib-specific-antibody-exhibits-potent-antitumor-activity-against-human-cancers-driven-by-activated-fgfr2-signaling/ 2024-05-31T17:24:46+00:00 https://aveo-staging.lumanitydigital.net/lg-chem-company-and-aveo-oncology-announce-lg-chems-first-proprietary-anti-cancer-compound-enters-phase-1-clinical-study-dosing-initiated-in-the-u-s/ 2024-06-13T16:42:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-announces-phase-3-renal-cell-carcinoma-clinical-trial-tinivo-2-results/ 2024-08-27T17:41:49+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-announces-acceptance-of-late-breaking-oral-presentation-of-tinivo-2-results-at-esmo-2024/ 2024-09-03T20:24:15+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-present-tinivo-2-results-and-tivo-3-exploratory-post-immunotherapy-survival-analysis-at-esmo-2024/ 2024-11-22T16:56:22+00:00 https://aveo-staging.lumanitydigital.net/tivozanib-plus-nivolumab-versus-tivozanib-monotherapy-in-patients-with-renal-cell-carcinoma-following-an-immune-checkpoint-inhibitor-results-of-the-phase-3-tinivo-2-study/ 2024-12-09T17:16:13+00:00 https://aveo-staging.lumanitydigital.net/cancer-cachexia-society-2023-congress/ 2024-12-10T15:44:14+00:00 https://aveo-staging.lumanitydigital.net/long-term-survival-in-patients-with-relapsed-refractory-advanced-renal-cell-carcinoma-treated-with-tivozanib-analysis-of-the-phase-iii-tivo-3-trial/ 2024-12-10T17:07:31+00:00 https://aveo-staging.lumanitydigital.net/tivozanib-versus-sorafenib-in-patients-with-advanced-renal-cell-carcinoma-tivo-3-a-phase-3-multicentre-randomised-controlled-open-label-study/ 2024-12-10T17:07:53+00:00 https://aveo-staging.lumanitydigital.net/activity-of-tivozanib-in-non-clear-cell-renal-cell-carcinoma-subgroup-analysis-from-a-phase-ii-randomized-discontinuation-trial-oncologist/ 2024-12-10T17:08:05+00:00 https://aveo-staging.lumanitydigital.net/inhibition-of-met-signaling-with-ficlatuzumab-in-combination-with-chemotherapy-in-refractory-aml-clinical-outcomes-and-high-dimensional-analysis/ 2024-12-10T17:09:15+00:00 https://aveo-staging.lumanitydigital.net/tinivo-safety-and-efficacy-of-tivozanib-nivolumab-combination-therapy-in-patients-with-metastatic-renal-cell-carcinoma/ 2024-12-10T17:09:50+00:00 https://aveo-staging.lumanitydigital.net/final-overall-survival-results-from-a-phase-3-study-to-compare-tivozanib-to-sorafenib-as-third-or-fourth-line-therapy-in-subjects-with-metastatic-renal-cell-carcinoma/ 2024-12-10T17:10:12+00:00 https://aveo-staging.lumanitydigital.net/a-multicentre-phase-i-study-of-ficlatuzumab-and-cetuximab-in-cetuximab-resistant-recurrent-metastatic-head-and-neck-cancer/ 2024-12-10T17:10:34+00:00 https://aveo-staging.lumanitydigital.net/real-world-results-from-one-year-of-therapy-with-tivozanib/ 2024-12-10T17:10:59+00:00 https://aveo-staging.lumanitydigital.net/efficacy-of-tivozanib-treatment-after-sorafenib-in-patients-with-advanced-renal-cell-carcinoma-crossover-of-a-phase-3-study/ 2024-12-10T17:11:27+00:00 https://aveo-staging.lumanitydigital.net/phase-1b-trial-of-ficlatuzumab-a-humanized-hepatocyte-gth-factor-inhibitory-monoclonal-antibody-in-combination-with-gefitinib-in-asian-patients-with-nsclc/ 2024-12-10T17:12:06+00:00 https://aveo-staging.lumanitydigital.net/a-randomized-phase-2-study-comparing-the-combination-of-ficlatuzumab-and-gefitinib-with-gefitinib-alone-in-asian-patients-with-advanced-stage-pulmonary-adenocarcinoma/ 2024-12-10T17:12:31+00:00 https://aveo-staging.lumanitydigital.net/tivozanib-versus-sorafenib-as-initial-targeted-therapy-for-patients-with-metastatic-renal-cell-carcinoma-results-from-a-phase-iii-trial/ 2024-12-10T17:12:54+00:00 https://aveo-staging.lumanitydigital.net/antitumor-activity-and-safety-of-tivozanib-av-951-in-a-phase-ii-randomized-discontinuation-trial-in-patients-with-renal-cell-carcinoma/ 2024-12-10T17:13:18+00:00 https://aveo-staging.lumanitydigital.net/biological-and-clinical-activity-of-tivozanib-a-selective-inhibitor-of-vegf-receptor-1-2-and-3-tyrosine-kinases-in-a-4-week-on-2-week-off-schedule-in-patients-with-advanced-solid-tumors/ 2024-12-10T17:13:42+00:00 https://aveo-staging.lumanitydigital.net/development-of-second-generation-vegfr-tyrosine-kinase-inhibitors-current-status/ 2024-12-10T17:14:04+00:00 https://aveo-staging.lumanitydigital.net/sitc-2023-fierce-hn-a-multicenter-randomized-placebo-controlled-phase-3-study-of-ficlatuzumab-cetuximab-in-pts-w-recurrent-or-metastatic-r-m-hpv-negative-head-and-neck-squamous-cell-carcinom/ 2024-12-10T17:33:36+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2023-estimated-cost-of-adverse-event-management-for-patients-with-metastatic-renal-cell-carcinoma-treated-with-vegfr-tki/ 2024-12-10T17:34:31+00:00 https://aveo-staging.lumanitydigital.net/asco-2022-activity-of-tivozanib-in-non-clear-cell-renal-cell-carcinoma-nccrcc-subgroup-analysis-from-a-phase-2-randomized-discontinuation-trial/ 2024-12-10T17:37:33+00:00 https://aveo-staging.lumanitydigital.net/asco-2022-maturation-of-overall-survival-in-tivo-3-with-long-term-follow-up/ 2024-12-10T17:38:09+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2022-tinivo-2-a-phase-3-randomized-controlled-open-label-study-to-compare-tivozanib-in-combo-with-nivolumab-to-tivozanib-monotherapy-in-patients-with-rcc-following-1-or-2-lines-of-therapy/ 2024-12-10T17:38:49+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2022-long-term-pfs-from-tivo-3-tivozanib-tivo-vs-sorafenib-sor-in-relapsed-refractory-r-r-advanced-rcc/ 2024-12-10T17:39:11+00:00 https://aveo-staging.lumanitydigital.net/asco-gi-2022-a-phase-1b-2-study-of-tivozanib-in-combination-with-durvalumab-in-subjects-with-advanced-hepatocellular-carcinoma-deductive-efficacy-results-in-previously-untreated-patients/ 2024-12-10T17:39:55+00:00 https://aveo-staging.lumanitydigital.net/asco-2021-randomized-phase-ii-trial-of-ficlatuzumab-with-or-without-cetuximab-in-pan-refractory-advanced-head-and-neck-squamous-cell-carcinoma-hnscc/ 2024-12-10T17:40:12+00:00 https://aveo-staging.lumanitydigital.net/asco-2021-tivo-3-durability-of-response-and-updated-overall-survival-of-tivozanib-vs-sorafenib-in-metastatic-renal-cell-carcinoma-mrcc/ 2024-12-10T17:40:41+00:00 https://aveo-staging.lumanitydigital.net/asco-2021-temporal-characteristics-of-treatment-emergent-adverse-events-and-dose-modifications-with-tivozanib-and-sorafenib-in-the-phase-3-tivo-3-study-of-relapsed-or-refractory-mrcc/ 2024-12-10T17:40:57+00:00 https://aveo-staging.lumanitydigital.net/asgo-gu-2021-q-twist-analysis-of-tivozanib-versus-sorafenib-in-patients-with-advanced-renal-cell-carcinoma-rcc-in-the-tivo-3-study/ 2024-12-10T17:41:14+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2021-tivozanib-in-patients-with-advanced-renal-cell-carcinoma-arcc-who-have-progressed-after-prior-treatment-with-axitinib-results-from-tivo-3/ 2024-12-10T17:41:44+00:00 https://aveo-staging.lumanitydigital.net/asco-gi-2021-deductive-a-study-of-tivozanib-in-combination-with-durvalumab-in-subjects-with-untreated-advanced-hepatocellular-carcinoma-phase-ib-results/ 2024-12-10T17:41:59+00:00 https://aveo-staging.lumanitydigital.net/asco-2020-tivo-3-final-os-analysis-of-a-phase-iii-randomized-controlled-multicenter-open-label-study-to-compare-tivozanib-to-sorafenib-in-subjects-with-metastatic-renal-cell-carcinoma-rcc/ 2024-12-10T17:42:16+00:00 https://aveo-staging.lumanitydigital.net/asco-gi-2020-phase-1b-study-of-gemcitabine-nab-paclitaxel-and-ficlatuzumab-in-patients-with-advanced-pancreatic-cancer/ 2024-12-10T17:42:37+00:00 https://aveo-staging.lumanitydigital.net/kcs-2019-tivo-3-a-phase-3-study-to-compare-tivozanib-to-sorafenib-in-subjects-with-refractory-advanced-renal-cell-carcinoma-rcc-overall-survival-2-year-update/ 2024-12-10T17:42:57+00:00 https://aveo-staging.lumanitydigital.net/esmo-2019-tinivo-tivozanib-combined-with-nivolumab-results-in-prolonged-progression-free-survival-in-patients-with-metastatic-renal-cell-carcinoma-mrcc-final-results/ 2024-12-10T17:43:12+00:00 https://aveo-staging.lumanitydigital.net/asco-2019-tivo-3-subgroup-analysis-of-progression-free-survival-of-tivozanib-compared-to-sorafenib-in-subjects-with-refractory-advanced-renal-cell-carcinoma-rcc/ 2024-12-10T17:43:28+00:00 https://aveo-staging.lumanitydigital.net/aacr-2019-cyfi-results-from-a-phase-ib-expansion-cohort-of-ficlatuzumab-fi-combined-with-high-dose-cytarabine-cy-in-patients-with-high-risk-relapsed-or-refractory-acute-myeloid-leukemia-aml/ 2024-12-10T17:43:45+00:00 https://aveo-staging.lumanitydigital.net/tivo-3-a-phase-3-randomized-controlled-multi-center-open-label-study-to-compare-tivozanib-to-sorafenib-in-subjects-with-refractory-advanced-renal-cell-carcinoma-rcc/ 2024-12-10T17:44:03+00:00 https://aveo-staging.lumanitydigital.net/randomized-phase-ii-study-of-ficlatuzumab-with-or-without-cetuximab-in-patients-with-cetuximab-resistant-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma/ 2024-12-10T17:44:39+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2018-tivozanib-combined-with-nivolumab-phase-ib-ii-study-in-metastatic-renal-cell-carcinoma/ 2024-12-10T17:44:54+00:00 https://aveo-staging.lumanitydigital.net/kcs-2017-tinivo-a-phase-ib-dose-escalation-trial-of-tivozanib-and-nivolumab-in-renal-cell-carcinoma/ 2024-12-10T17:45:52+00:00 https://aveo-staging.lumanitydigital.net/phase-i-study-of-the-anti-hgf-monoclonal-antibody-ficlatuzumab-and-cetuximab-in-cetuximab-resistant-recurrent-metastatic-head-and-neck-cancer/ 2024-12-10T17:46:10+00:00 https://aveo-staging.lumanitydigital.net/asco-2017-cyfi-a-phase-i-study-exploring-the-role-of-cmet-pathway-inhibition-with-ficlatuzumab-fi-combined-with-high-dose-cytarabine-cy-in-patients-with-high-risk-relapsed-or-refractory-acute-my/ 2024-12-10T17:46:25+00:00 https://aveo-staging.lumanitydigital.net/asco-2017-tivo-3-a-phase-3-randomized-controlled-multi-center-open-label-study-to-compare-tivozanib-hydrochloride-to-sorafenib-in-subjects-with-refractory-advanced-renal-cell-carcinoma-rcc/ 2024-12-10T17:46:51+00:00 https://aveo-staging.lumanitydigital.net/asco-2015-tivozanib-vs-sorafenib-targeted-therapy-for-advanced-renal-cell-carcinoma-final-results-of-a-phase-3-trial-901-and-efficacy-results-of-a-second-line-tivozanib-extension-study-902/ 2024-12-10T17:47:07+00:00 https://aveo-staging.lumanitydigital.net/circulating-neuropilin-1-as-a-potential-biomarker-of-progression-free-survival-benefit-for-tivozanib-in-metastatic-clear-cell-renal-cell-carcinoma-rcc-post-hoc-biomarker-analysis-of-tivozanib-rcc-t/ 2024-12-10T17:47:21+00:00 https://aveo-staging.lumanitydigital.net/esmo-2014-efficacy-analysis-of-gefitinib-ficlatuzumab-in-serum-proteomic-based-subgroups-of-patients-with-previously-untreated-lung-adenocarcinoma/ 2024-12-10T17:47:40+00:00 https://aveo-staging.lumanitydigital.net/esmo-2014-phase-2-clinical-evaluation-of-preclinically-defined-biomarkers-for-vascular-endothelial-growth-factor-tyrosine-kinase-inhibitor-tivozanib-in-renal-cell-carcinoma/ 2024-12-10T17:47:56+00:00 https://aveo-staging.lumanitydigital.net/efficacy-and-safety-data-from-patients-with-advanced-renal-cell-cancer-treated-with-tivozanib-hydrochloride-after-progression-on-sorafenib/ 2024-12-10T17:48:16+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2013-tivozanib-tivo-1-subgroups-abstract-354-hutson/ 2024-12-10T17:48:34+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2013-tivozanib-tivo-1-qol-abstract-355-cella/ 2024-12-10T17:48:52+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2013-tivozanib-tivo-1-hypoxia-signature-ccrcc-abstract-361-robinson/ 2024-12-10T17:49:08+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2013-tivozanib-study-902-efficacy-safety-abstract-364-motzer/ 2024-12-10T17:49:25+00:00 https://aveo-staging.lumanitydigital.net/asco-gu-2013-tivozanib-tivo-1-overall-survival-abstract-350-motzer/ 2024-12-10T17:49:51+00:00 https://aveo-staging.lumanitydigital.net/esmo-2012-tivo-1-safety-poster-eisen/ 2024-12-10T17:50:03+00:00 https://aveo-staging.lumanitydigital.net/esmo-2012-tivozanib-pkpd-poster-escudier/ 2024-12-10T17:50:19+00:00 https://aveo-staging.lumanitydigital.net/esmo-2012-taurus-trial-in-progress-poster-nosov/ 2024-12-10T17:50:34+00:00 https://aveo-staging.lumanitydigital.net/esmo-2012-ficlatuzumab-pkpd-poster-baselga/ 2024-12-10T17:50:52+00:00 https://aveo-staging.lumanitydigital.net/esmo-2012-ficlatuzumab-phase-2-nsclc-poster-mok/ 2024-12-10T17:51:07+00:00 https://aveo-staging.lumanitydigital.net/asco-2012-baton-rcc-trial-overview-poster/ 2024-12-10T17:51:26+00:00 https://aveo-staging.lumanitydigital.net/asco-2012-tivozanib-folfox6-ph1b-final-results/ 2024-12-10T17:51:42+00:00 https://aveo-staging.lumanitydigital.net/2012-asco-annual-meeting-tivozanib-phase-3-tivo-1-data-oral-presentation-abstract-4501/ 2024-12-10T17:52:11+00:00 https://aveo-staging.lumanitydigital.net/aacr-annual-meeting-2012-tivozanib-food-effect-poster/ 2024-12-10T17:52:31+00:00 https://aveo-staging.lumanitydigital.net/aacr-nci-eortc-tivozanib-ph1-qtc-study-poster/ 2024-12-10T17:52:49+00:00 https://aveo-staging.lumanitydigital.net/aacr-nci-eortc-tivozanib-vegfc-poster/ 2024-12-10T17:53:05+00:00 https://aveo-staging.lumanitydigital.net/emuc-2011-results-from-phase-1-trial-of-tivozanib-combined-with-temsirolimus-in-patients-with-rcc/ 2024-12-10T17:53:46+00:00 https://aveo-staging.lumanitydigital.net/2011-asco-annual-meeting-tivozanib-phase-2-final-analysis-poster/ 2024-12-10T17:54:06+00:00 https://aveo-staging.lumanitydigital.net/2011-asco-annual-meeting-tivozanib-torisel-phase-1b-data-poster/ 2024-12-10T17:54:22+00:00 https://aveo-staging.lumanitydigital.net/2011-asco-annual-meeting-ficlatuzumab-phase-2-trial-in-progress-poster/ 2024-12-10T17:54:37+00:00 https://aveo-staging.lumanitydigital.net/2011-asco-annual-meeting-ficlatuzumab-gefitinib-phase-1b-data-poster/ 2024-12-10T17:54:49+00:00 https://aveo-staging.lumanitydigital.net/eortc-nci-aacr-2010-tivozanib-biomarker-poster/ 2024-12-10T17:55:09+00:00 https://aveo-staging.lumanitydigital.net/ikcs-2010-tivozanib-phase-2-hypertension-poster/ 2024-12-10T17:55:23+00:00 https://aveo-staging.lumanitydigital.net/ikcs-2010-tivozanib-phase-2-histologic-subtypes-poster/ 2024-12-10T17:55:42+00:00 https://aveo-staging.lumanitydigital.net/asco-2010-tivozanib-poster/ 2024-12-10T17:55:56+00:00 https://aveo-staging.lumanitydigital.net/asco-2010-av-299-poster/ 2024-12-10T17:56:11+00:00 https://aveo-staging.lumanitydigital.net/2010-genitourinary-cancers-symposium-presentation/ 2024-12-10T17:56:25+00:00 https://aveo-staging.lumanitydigital.net/asco-gi-2023/ 2024-12-10T17:58:06+00:00 https://aveo-staging.lumanitydigital.net/asco-gi-2022-a-phase-1b-2-open-label-study-of-tivozanib-in-combination-with-durvalumab-in-subjects-with-advanced-hepatocellular-carcinoma-deductive/ 2024-12-10T17:59:38+00:00 https://aveo-staging.lumanitydigital.net/estimated-cost-of-vegfr-tki-associated-adverse-events-in-metastatic-renal-cell-carcinoma-patients/ 2024-12-10T22:16:00+00:00 https://aveo-staging.lumanitydigital.net/advanced-human-papillomavirus-negative-head-and-neck-squamous-cell-carcinoma-unmet-need-and-emerging-therapies/ 2024-12-10T22:18:49+00:00 https://aveo-staging.lumanitydigital.net/randomized-phase-ii-trial-of-ficlatuzumab-with-or-without-cetuximab-in-pan-refractory-recurrent-metastatic-head-and-neck-cancer/ 2024-12-10T22:21:15+00:00 https://aveo-staging.lumanitydigital.net/tinivo-2-presentation-from-esmo-2024/ 2024-12-10T22:23:58+00:00 https://aveo-staging.lumanitydigital.net/tinivo-tivozanib-combined-with-nivolumab-safety-and-efficacy-in-patients-with-metastatic-renal-cell-carcinoma-mrcc/ 2024-12-11T19:51:37+00:00 https://aveo-staging.lumanitydigital.net/aacr-nci-eortc-tivozanib-ph1-adme-study-poster/ 2024-12-11T19:53:31+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-announces-tivozanib-presentations-at-asco-gu-2025/ 2025-02-14T21:15:48+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-presents-two-posters-for-tivozanib-at-the-2025-asco-gu-meeting/ 2025-02-18T22:13:04+00:00 https://aveo-staging.lumanitydigital.net/integrated-efficacy-and-safety-exposure-response-er-analysis-of-tivozanib-tivo-for-the-treatment-of-renal-cell-carcinoma-rcc/ 2025-04-04T20:56:45+00:00 https://aveo-staging.lumanitydigital.net/patient-reported-outcomes-pros-for-tivozanib-nivolumab-tivo-nivo-vs-tivozanib-tivo-monotherapy-in-patients-with-renal-cell-carcinoma-rcc-following-an-immune-checkpoint-inhibitor-ici-resu/ 2025-04-04T20:57:05+00:00 https://aveo-staging.lumanitydigital.net/updated-overall-survival-in-patients-with-prior-checkpoint-inhibitor-therapy-in-the-phase-iii-tivo-3-study/ 2025-04-04T20:57:29+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-announces-three-poster-presentations-at-asco-2025-annual-meeting/ 2025-04-30T15:15:49+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-presents-three-posters-at-asco-2025-annual-meeting/ 2025-11-04T15:54:54+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-and-hibercell-enter-into-an-exclusive-development-and-option-agreement-for-first-in-human-compound/ 2025-11-04T16:00:29+00:00 https://aveo-staging.lumanitydigital.net/overview-of-tivozanib-tivo-safety-in-patients-with-metastatic-renal-cell-carcinoma-mrcc/ 2025-11-21T17:48:10+00:00 https://aveo-staging.lumanitydigital.net/fierce-hn-a-multicenter-randomized-double-blind-placebo-controlled-phase-3-study-of-ficlatuzumab-hgf-c-met-mab-in-combination-with-cetuximab-in-participants-with-recurrent-or-metastatic-r-m-h/ 2025-11-21T17:48:54+00:00 https://aveo-staging.lumanitydigital.net/efficacy-of-second-line-2l-treatment-with-tivozanib-tivo-as-monotherapy-or-with-nivolumab-nivo-in-patients-pts-with-metastatic-renal-cell-carcinoma-mrcc-previously-treated-with-an-immune-che/ 2025-11-21T17:48:58+00:00 https://aveo-staging.lumanitydigital.net/a-phase-1b-dose-escalation-study-of-av-380-anti-gdf15-monoclonal-antibody-in-combination-with-standard-of-care-therapy-in-cancer-patients-with-cachexia/ 2025-11-21T17:49:01+00:00 https://aveo-staging.lumanitydigital.net/cancer-cachexia-marker-growth-differentiation-factor-15-gdf-15-serum-level-mapping-in-real-world-samples-from-patients-with-pancreatic-panc-or-colorectal-cancer-crc/ 2025-11-21T17:50:59+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-announces-first-patient-dosed-in-front-line-aml-combination-study-of-ficlatuzumab/ 2026-01-14T17:30:16+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-announces-completion-of-the-first-interim-analysis-in-the-global-phase-3-fierce-hn-study/ 2026-02-18T15:51:38+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-an-lg-chem-company-announces-two-poster-presentations-at-asco-2026-annual-meeting/ 2026-05-05T14:53:35+00:00 https://aveo-staging.lumanitydigital.net/aveo-oncology-announces-succession-plan/ 2026-06-30T15:03:02+00:00